|
EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Contributors were selected by Jean
A. Maroun, MD, FRCPC, FRCP; Joseph Ragaz, MD, FRCPC; and Amil
Shah, MD, FRCPC
Colorectal
cancer
Lyly H. Lê, MDCM, FRCPC
RANDOMIZED PHASE III STUDY OF
CAPECITABINE, OXALIPLATIN, AND BEVACIZUMAB WITH OR WITHOUT
CETUXIMAB IN ADVANCED COLORECTAL CANCER (ACC), THE CAIRO2
STUDY OF THE DUTCH COLORECTAL CANCER GROUP (DCCG). ASCO 2008,
ABSTRACT LBA4011.
Investigators: C.J. Punt
et al.
Pancreatic
cancer
Howard
J. Lim, MD, PhD, FRCPC and Hagen Kennecke, MD, MPH, FRCPC
CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER
PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE
VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER
(PC). ASCO 2008, ABSTRACT LBA4504.
Investigators: P. Neuhaus et
al.
Early-stage
breast cancer
Caroline
Lohrisch, MD, FRCPC
STANDARD CHEMOTHERAPY (CMF OR AC) VERSUS CAPECITABINE IN EARLY-STAGE
BREAST CANCER (BC) PATIENTS AGED 65 AND OLDER: RESULTS OF
CALGB/CTSU 49907. ASO 2008, ABSTRACT 507.
Investigators: H.B. Muss et
al.
INTERIM RESULTS OF INTERGROUP EC-DOC
TRIAL: A RANDOMIZED MULTICENTER PHASE III TRIAL COMPARING
ADJUVANT CEF/CMF TO EC- DOCETAXEL IN PATIENTS WITH 1-3 POSITIVE
LYMPH NODES. ASCO 2008, ABSTRACT 515.
Investigators: U. Nitz et al.
RANDOMIZED PHASE III TRIAL COMPARING
THE SEQUENTIAL ADMINISTRATION OF DOCETAXEL FOLLOWED BY EPIRUBICIN
PLUS CYCLOPHOSPHAMIDE VERSUS FE75C AS ADJUVANT CHEMOTHERAPY
IN AXILLARY LYMPH NODE-POSITIVE BREAST CANCER. ASCO 2008,
ABSTRACT 521.
Investigators: D. Mavroudis
et al.
Premenopausal
breast cancer
Debjani
Grenier, MD, FRCPC
ADJUVANT OVARIAN SUPPRESSION COMBINED WITH TAMOXIFEN OR ANASTROZOLE,
ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID, IN PREMENOPAUSAL
WOMEN WITH HORMONE-RESPONSIVE, STAGE I AND II BREAST CANCER:
FIRST EFFICACY RESULTS FROM ABCSG-12. ASCO 2008, ABSTRACT
LBA4.
Investigators: M. Gnant et al.
Vitamin
D and breast cancer
Joseph
Ragaz, MD, FRCPC
FREQUENCY OF VITAMIN D (VIT D) DEFICIENCY AT BREAST CANCER
(BC) DIAGNOSIS AND ASSOCIATION WITH RISK OF DISTANT RECURRENCE
AND DEATH IN A PROSPECTIVE COHORT STUDY OF T1-3, N0-1, M0
BC. ASCO 2008, ABSTRACT 511.
Investigators: P.J. Goodwin
et al.
|
